

# Index

**Note:** The letters 'f' and 't' following locators refer to figures and tables respectively.

## A

- AASLD, *see* American Association for the Study of Liver Diseases (AASLD)
- AASLD guidelines for ultrasound surveillance, 63
- AATD, *see*  $\alpha_1$  Antitrypsin deficiency (AATD)
- Abdalla, E. K., 109–129, 176, 176
- Abe, T., 282
- Ablative procedures
- cryoablation, 84
  - microwave, 84
  - radiofrequency, 84
- Abou-Alfa, G. K., 355–364, 376
- Acetic acid injection, 268
- Acidic fibroblast growth factor (aFGF), 26
- Advanced HCC, 70, 93, 95, 119, 219, 358, 360–361, 369, 376t, 379
- aFGF, *see* Acidic fibroblast growth factor (aFGF)
- Aflatoxin (AF), 6, 24, 57, 100, 105  
*See also* Aflatoxin B1 (AFB1)
- Aflatoxin B1 (AFB1), 23, 105, 288
- AFP, *see* Alpha-fetoprotein (AFP)
- AFP-L3, 61, 384
- AF, *see* Aflatoxin (AF)
- AJCC/UICC staging system, *see* American Joint Committee on Cancer/International Union Against Cancer (AJCC/UICC) staging system
- Alagille syndrome, 28
- Albany, C., 355–365
- Albumin, 45–46
- Alcohol consumption and HCC, 4–5
- Aloia, T. A., 219–232
- Alpha-fetoprotein (AFP), 37, 42, 46, 58–64, 82, 101, 102t, 111, 127–128, 130, 222, 230, 241, 307, 331, 346, 375f, 384
- American Association for the Study of Liver Diseases (AASLD), 55, 63, 82, 91
- American Joint Committee on Cancer (AJCC), 69, 73–76, 74t, 175, 222, 256
- American Joint Committee on Cancer/International Union Against Cancer (AJCC/UICC) staging system, 69, 74–78, 74t
- Anatomic segmentectomy, 191
- Andrews, J., 322
- Angiogenesis, 25–27
- angiopoietins, role in, 26
  - FGF, pro-angiogenic activity, 26
  - neovasculature in tumour, role in cancer growth, 25
  - 'vascular mimicry,' 26
  - VEGF, role in tumour development, 26
- Angiopoietin-2 (Ang-2), 364
- Angiopoietins, 26, 364
- Antero-lateral liver segments, *see* Laparoscopic liver segments
- Ante situm* technique, 252, 254
- $\alpha_1$  Antitrypsin deficiency (AATD), 12, 28, 287
- Apoptosis, 7, 10, 21–23, 47, 155–157, 343, 357, 371
- Aquamantys™, 213
- Argon beam coagulator, 125
- Asia-Pacific trial, 357–358
- Aspergillus*, 105
- Atrophy (shrinkage) of hepatic segments, 153–154
- Atypical resection (laparoscopic)/segmentectomy, 187, 190–194, 192f, 199f
- Avritscher, R., 153–178

**B**

- Backflow bleeding control, technique, 146–147  
 Ball valve thrombus syndrome, 246  
 Balmer, M. L., 21–30  
 Barcelona Clinic Liver Cancer (BCLC) staging system, 71, 73–74, 73t, 82, 221  
   patients with multifocal disease, treatment recommendations, 72  
 Basic fibroblast growth factor (bFGF), 26, 29t  
 BCLC staging system, *see* Barcelona clinic liver cancer (BCLC) staging system  
 Belghiti, J., 123, 128, 386  
 Belli, G., 194, 196, 200–202  
 Benign vs. malignant hepatic tumors, 46–48  
   CD 34, 46–47  
   glypican 3, 47  
     example, in grade III arising in cirrhotic lines, 48f  
     expression in hepatocytic nodules, 47t  
   HSP70, 47  
 Bevacizumab, 162, 346, 355, 358, 360, 363–364, 371, 372t, 373–374, 375f, 376t  
 bFGF, *see* Basic fibroblast growth factor (bFGF)  
 Bile duct stenosis, 283  
 Bi-lobar disease, 208  
 BioGlu (Cryolife), 214  
 Biology of HCC  
   biological features of liver cancer, 23–24  
     angiogenesis, 25–27  
     HCC in non-cirrhotic liver, 27–28  
     liver stem cells, 24–25  
     metastasis, 29–30  
     telomere shortening, 27  
   cancer cell survival, criteria  
     alterations in cell physiology, cause of malignant growth, 21  
     antiproliferative signals, 22  
     cancer metastasis, 23  
     growth signals, 22  
     induction of blood vessel formation by tumours, 23  
     long and winding road to cancer, 22f  
     resistance to apoptosis, 22–23  
     telomere maintenance, 23  
 Bismuth, H., 128  
 Blanchard, R. J., 321  
 Bland transarterial embolization, 168  
 Bortezomib, 345, 372t  
 Brivanib, 345, 364  
 Bruix, J., 112, 292  
 Bryant, R., 201, 210

- Budd–Chiari syndrome, 246  
 Buell, J. F., 186, 194, 201, 209–218  
*N*-Butyl cyanoacrylate (NBCA), 171  
*N*-Butyl-2-cyanoacrylate (NBCA), 170

**C**

- Cadaveric liver allografts/transplants, 220  
 Camp, E. R., 261–271  
 Cancer of the Liver Italian Program (CLIP) score, 69–70, 70t, 329  
   Japanese/Canadian validation study, 72  
   limitations, 73  
   vs. Okuda system, 73  
 Cancer stem cell (CSC), 25  
 “Capillarization” of sinusoids, 46  
 Carbon dioxide pneumoperitoneum, 188  
 Carcinogenic pathways, 370–371  
 Cardiac arrhythmia, 188  
 Carpanese, L. P. G., 331  
 Carr, B. I., 329  
 Carter, S., 297–315  
 Caudate lobectomies, 160, 198  
 CD 34, 46–47  
 CE-IOUS, *see* Contrast-Enhanced Intraoperative Ultrasonography (CE-IOUS)  
 Cetuximab, 355, 359, 371, 372t, 374, 376t  
 Charring, 277, 278  
 Chemoembolization, 291  
   *See also* Transarterial chemoembolization (TACE)  
 Chemotherapeutic beads, 209  
 Chemotherapeutic drugs, 337, 338t, 339  
 Chemotherapy, 38, 40, 84, 93, 117f, 118–120, 121f, 161–162, 223–225, 228–229, 243, 287–288, 289f–290f, 290, 293–295, 299–301, 303, 314, 321, 337–348, 369, 374, 377, 385  
   *See also* High-dose chemotherapy; Systemic chemotherapy  
 Chen, H. Y., 186, 194, 201  
 Chen, M. S., 266  
 Chen, T. M., 355  
 Cherqui, D., 185–202  
 Child–Pugh A disease, 91, 192, 295, 314, 330, 360–362  
 Child–Pugh B disease, 192–193, 202, 309, 361  
 Child–Pugh C disease, 241, 294, 294t, 314  
 Child–Pugh (CP) classification, 113–114, 113t  
 Child–Turcotte–Pugh (CTP) score, 221  
 Chinese University Prognostic Index (CUPI), 69, 73–74, 73t  
 Choi, H., 266, 268, 304

- Cholecystectomy, 10, 193, 328
- Cholelithiasis (gallbladder stones), 10
- Chronic active infection, 287
- Chronic alcoholism, 287
- Cirrhosis, characteristics, 24
- Cirrhotics, 192, 208–209, 212–213, 216, 331
- Cisplatin, 84, 223, 291, 338t, 339–341
- Clear cell HCC, 40
- Clinical Practice Guidelines for Hepatocellular Carcinoma (2005), 90, 93
- Clinical staging systems
  - BCLC staging system, 71–72, 71t
  - CLIP, 70–71, 70t
  - Okuda staging system, 70
- CLIP score, *see* Cancer of the liver Italian program (CLIP) score
- Coagulation necrosis, 276, 282
- Cold perfusion and *ex vivo* approach, 250
- Colectomy, laparoscopic, 193
- Colon cancer, 193, 200, 327
- Color-Doppler, 141, 147–148
- Combination systemic therapy, HCC
  - clinical trial design
    - assessment of, 378
    - key considerations, 378–379
    - traditional approach in oncology research, 378
  - current challenges, 376–377
  - existing evidence for benefit
    - four-phase imaging technique, 375f
  - growth factors as therapeutic targets
    - dysregulation in HCC, 373t
    - EGF signaling, inhibition, 371–372
  - key carcinogenic pathways, 371
  - molecular targeted therapy, 371
  - PI3K/Akt/mTOR pathway, 371
  - Ras–raf kinase pathway, 371
- Combined HCC and cholangiocarcinomas
  - (combined HCC–CC), 42–43, 42f
  - cirrhosis, HCC-predominant type cases, 42
  - hepatocytes/cholangiocytes, mechanisms of histogenesis, 42–43
- Common Terminology Criteria for Adverse Events (CTCAE), 294
- Computed tomographic perfusion, 363–364
- Computed tomography (CT), 55, 110, 112f, 115, 119f, 121f, 128, 157, 158f, 220, 242, 304, 357, 362, 375f, 377
- Concomitant hepatectomy, 283
- Contralateral liver, 154
- Contrast-enhanced imaging techniques, 363
- Contrast-Enhanced Intraoperative Ultrasonography (CE-IIOUS), 135, 139–140, 140f
- Contreras, C. M., 81–87
- Conventional Milan Criteria (CMC), 221, 226t, 232t
- Co-seal (Baxter), 214
- Cryoablation, 84, 207, 223–224, 268–273
- CSC, *see* Cancer stem cell (CSC)
- Cumulative absorbed lung radiation dose, 325
- CUPI, *see* Chinese University Prognostic Index (CUPI)
- Curettage and aspiration device, 190
- Curley, S. A., 261–271
- Cytokeratin, 41, 46
- Cytokines
  - interleukin-6, 155
  - tumor necrosis factor- $\alpha$ , 155
- Cytologic subtypes of HCC, 40–41
  - clear cell HCC, 40
  - pleomorphic HCCs, 40
  - spindle (sarcomatoid) tumor cells, 40f, 40
  - vascular invasion, risk factor, 41, 41f
- Cytotoxic chemotherapy/endocrine therapy
  - adjuvant therapy, 343–344
  - advanced, 337
  - combination chemotherapy, 340
  - novel approaches, 344
    - biomarker of response, AFP, 346
    - overcome drug resistance, strategies, 344–346
  - somatostatin analogues, 342–343
- D**
- Dancey, J. E., 328
- D’Avola, D. D., 331
- DC bead<sup>TM</sup>, 301, 303, 307
- DCE-MRI analyses, 363
- DCP, *see* Des-gamma carboxyprothrombin (DCP)
- DEB-TACE, *see* Drug-eluting beads transarterial chemoembolization (DEB-TACE)
- Degree of cirrhosis, 242, 261
- Des-gamma carboxy prothrombin (DCP), 61, 384
- Diabetes mellitus, 7–8, 105
  - and HCC risk, evidence, 7
  - mechanism for liver cell damage
    - insulin resistance and hyperinsulinemia, 7
- Dietary factors, risk, 10
- Diffuse type HCCs, 36

- DNA hepatitis B (Hep. B), 288
- DNs, *see* Dysplastic nodules (DNs)
- Doxorubicin, 84, 223, 293, 295, 295f, 301–303, 307–308, 311, 337–340, 338t, 345–346, 356, 376t
- Drug-eluting beads transarterial chemoembolization (DEB-TACE)
- clinical use, 306–311
    - PRECISION V trial, flowchart, 308f
  - delivery technique, 303
    - dose treatment schedule, 303
  - overall response, evaluation, 306
  - overall safety, 312
  - patient selection, 303
    - EASL staging, 300f
  - phase I–II studies, 302–303
    - drug distribution, 302f
  - response rates, 311–312
  - tumor response, calculation of, 304–305
    - EASL criteria, use of, 305
    - RECSIT criteria, modification, 304
    - target lesion, example, 305, 306f
    - treatment response assessment, 304
  - in vitro/in vivo* data, 301–302
    - delivery of, 302
      - doxorubicin drug-eluting bead by Lewis et al., 301
- Dufour, J.-F., 21–30
- Dysplasia, 28, 43
- Dysplastic nodules (DNs), 24–25, 43, 44f, 46, 47t, 73, 83, 139, 222, 373t
- E**
- Early Detection Research Network (EDRN), 55, 61
- Early HCCs, 35, 43–44, 44f, 46, 62, 71, 73, 76–77, 82–83, 140, 185, 220, 222
- See also* Well-differentiated HCCs
- EASL, *see* European Association for the Study of the Liver (EASL)
- EASL criteria, 290, 304–305, 309, 311, 314, 327
- Eastern Cooperative Oncology Group (ECOG), 294
- Edmondson grading scheme of HCC, 38
- EDRN, *see* Early Detection Research Network (EDRN)
- Embolization
- embolic agents, 171–172
    - cirrhosis or advanced fibrosis, 172
    - distal embolization, 172
  - drawbacks of NBCA embolization, 172
  - ethanol, 172
  - fibrin glue, 172
  - gelatin sponge, 171
  - metallic coils, 172
  - multiple microcatheters, 172
  - NBCA mixed with ethiodized oil, 171
  - polymerization time, 171
  - PVA and tris-acryl gelatin microspheres, 172
    - risk of non-target embolization, 172
  - extent of, 170–171
    - FLR hypertrophy, 170–171
    - left lateral bisegment hypertrophy, 171
    - liver hypertrophy, 171
    - risk of tumor growth, reduction of, 171
    - segment 4 hypertrophy, 170
  - sequential arterial, 168–170
  - TAE, 154
  - “Empiric method,” 326
- Endocrine therapy, 337–348
- End-stage liver, etiologies of, 230f
- Environmental risk factors
- aflatoxin exposure, 6
  - alcohol consumption
    - European study, dose-dependent risk, 4
    - seroepidemiological study, 5
    - US case–control study, variations in HCC risk by sex, 4–5
  - hormonal intake, 6
  - occupational exposures, 6
  - smoking, 5–6
- Epidemiology and pathogenesis
- HCC incidence, 1
  - risk factors of HCC
    - chronic medical conditions, 7–10
    - dietary factors, 10
    - environmental risk factors, 4–6
    - genetic risk factors, 11
    - hepatitis virus infection, 2–4
    - inherited diseases, 11–12
- Epidermal growth factor (EGF), 155, 356f, 359, 371, 373t
- Epidermal growth factor receptor (EGFR), 358–359, 371, 372t–373t, 374
- Epirubicin, 338t, 339–340, 345
- Erlotinib
- adverse events, 359–360
  - independent phase II study, 360
  - median overall survival, 360
  - side effects, 360
- Ertle, J., 330
- Esnaola, N. F., 261–271
- European Association for the Study of the Liver (EASL), 305

- Evident<sup>TM</sup> Microwave Ablation System, 279
- Exophytic lesions, 192
- Extrahepatic disease, 111, 112f, 209, 211, 280, 305, 384–385
- “Extreme operations,” 255
- Ex vivo* liver resection, 250, 253
- F**
- Facciuto, M. E., 388
- Farges, O., 160–161, 174, 176, 387
- Feilchenfeldt, J. W., 355–365
- FGF, *see* Fibroblast growth factor (FGF)
- FGFR, *see* Fibroblast growth factor receptor (FGFR)
- Fibroblast growth factor (FGF), 23, 26, 345, 359, 373t, 374
- Fibroblast growth factor receptor (FGFR), 359, 374
- Fibrolamellar carcinoma (FLC/FLHCC), 41–42, 103–104, 128–129
- Fibrotic/cirrhotic liver, 208
- FLC/FLHCC, *see* Fibrolamellar carcinoma (FLC/FLHCC)
- FLC vs. traditional HCC, 104, 104t
- Follow-up/salvage therapy, HCC
  - after resection/ablation, 384
    - proposed algorithm for treatment, 386f
    - tumor markers, role of, 384
  - patients with hepatic recurrence, salvage therapy, 387t
    - multivariate analysis, 385
    - repeat hepatic resection, 387t
    - review by Poon et al., 385–386
    - review by Shah et al., 385
    - salvage vs. primary liver transplantation, 388
    - transarterial chemoembolization, 388t
    - treatment modalities, 384
- Fong, Y., 103
- Future liver remnant (FLR)
  - volume measurement and function, 157–159
    - axial image reconstruction, 159
    - computed tomography (CT) volumetry, 157
  - degree of hypertrophy (DH), 158
  - FLR/TELV ratio, 158
  - hypertrophy of FLR after PVE, 158f
  - indocyanine green retention at 15 min (ICGR15), 157
  - measurement of total liver volume (TLV), 157
  - multiphasic contrast-enhanced CT, 157
  - single-photon emission scintigraphy, 159
  - “standardized FLR measurement,” 158
  - three-dimensional CT volumetric measurements, 157
  - TLV minus tumor volume, 157
  - total estimated liver volume (TELV), 158
- G**
- Gaber O. A., 219–232
- Gadolinium, 83, 209, 242
- Gallbladder cancers, 200
- Gas embolism, 185, 187–188, 195
- Gasless laparoscopy, 188
- Gastric alcohol dehydrogenase, 4–5
- Gaudio, D., 388
- Gefitinib, 359, 371, 374t
- Gemcitabine, 338t, 341, 346, 364, 376t
- Genetic aberrations in HCC, 24
- Genetic risk factors, 11
- Georgiades, C., 287–296
- Geschwind, J. F., 287–296, 329
- Ghobrial, R. M., 219–232
- Glisson’s capsule, 137
- Glycogen storage disorder disease type I (von Gierke’s disease), 12
- Glypican 3
  - example, in grade III arising in cirrhotic livers, 48f
  - expression in hepatocytic nodules, 47t
- Goin, J., 328
- G. Pascale National Cancer Institute, 265, 268
- Grady, E., 321
- Gulec, S. A., 328, 330
- Gupta, S., 319–332
- H**
- Habib 4X<sup>TM</sup>, 213
- Hand-assisted laparoscopy, 188, 191
- Harmonic Scalpel<sup>TM</sup>, 190, 199f, 213–214
- Hasegawa, K., 89–96
- Hassan, M. M., 1–12, 57
- Hayashi, H., 11
- HBe-antigen/antibody status, 56–57
- HBsAg, *see* Hepatitis B surface antigen (HBsAg)
- HBV, *see* Hepatitis B virus (HBV)
- HBV genotypes, 2
- HBV vaccination, 2
- HCC in non-fibrotic liver, 101–103
  - aflatoxin AFB1 produced by *Aspergillus*, 105

- HCC in non-fibrotic liver (*cont.*)  
 age-specific increase in HCC (Kentucky),  
 102–103, 103f  
 features of non-cirrhotic hepatoma, 102t  
 FLC, 103–104  
 histologic appearance, 103  
 tumors of youth and young  
 adulthood, 103  
 vs. traditional HCC, 104t
- HH  
 autosomal recessive syndrome of iron  
 overload, 104  
 longitudinal cohort study in Italy, 105  
 missense mutations at HFE, cause,  
 104–105
- NAFLD  
 NASH-associated cirrhosis, 106  
 potential etiologies for increased incidence  
 of HCC, 101  
 radiologic presentation of a cirrhotic  
 HCC, 102f
- HCC in non-viral, non-alcoholic liver  
 HCC in non-fibrotic liver, 101–103  
 aflatoxin, 105  
 FLC, 103–104  
 HH, 104–105  
 NAFLD, 105–106  
 risk factors, 99–100  
 potential causes of non-cirrhotic  
 hepatocellular cancer, 100f
- HCC staging systems  
 BCLC staging system, 82  
 TNM staging system, 82
- HCC vs. metastatic adenocarci-  
 noma/cholangiocarcinoma,  
 45–46  
 albumin, 45–46  
 alpha-fetoprotein, 46  
 cytokeratin, 46  
 HepPar1, 46  
 mucin, 45  
 polyclonal CEA and CD10, 46
- HCV, *see* Hepatitis C virus (HCV)
- Heat shock protein 70 (HSP70), 47
- Heat sink effect, 277, 283
- Hedgehog (Hh) responsive tumors, 25, 364
- Helical CT, 62, 264–265
- Helix Hydro-jet™, 213
- Hemihepatectomy, 114, 141, 280
- Hemming, A. W., 129, 176, 239–255
- Hemochromatosis, 42, 100, 287  
*See also* Hereditary hemochromatosis  
 (HH/HHC)
- Hemostasis, 124, 189, 214, 277, 279
- Hepatectomy, 76, 83, 85f–86f, 104, 110–118,  
 118f–119f, 121f, 122–123,  
 126–127, 141–142, 147–148,  
 153–156, 159–162, 164, 166f–167f,  
 168, 169f, 170–172, 173–177, 176t,  
 186–187, 187f, 189–191, 198–199,  
 202, 210, 212t, 213, 241–243, 253,  
 275, 280, 282–283, 320f, 375f, 385
- Hepatic arterial infusion therapy, 92
- Hepatic artery delivery via embolization, 320f
- Hepatic disease, 111, 112f, 128, 172, 185, 207,  
 209, 261, 265, 275, 280, 305, 323,  
 383–385
- Hepatic resection, *see* Laparoscopic liver  
 resection for HCC
- Hepatic resection with vascular reconstruction,  
 244–245  
 lesions involving hilar vessels, 244–245  
 adenocarcinomas, 244  
 end-to-end anastomosis, 244  
 hilar vessels, 244  
 ipsilateral portal vein, 244  
 parenchymal transection, 244  
 portal blood flow, 244  
 resection of tumor, 246f  
 thrombectomy, 245  
 tumor embolus/thrombi, 244  
 ultrasonography, 244
- Hepatic stellate cells (HSCs), 3, 373t
- Hepatic/vascular resections, intraoperative  
 strategies, 243–244  
 atraumatic vascular clamp, 243  
 central venous pressure (CVP), 243  
 diuresis, 243  
 fluid restriction, 243  
 IL-6 and STAT3, 243  
 inflow occlusion, 243  
 meta-analysis, 244  
 Pringle maneuver, 243–244  
 trendelenburg position, 243  
 vasodilators, 243
- Hepatic vein and IVC involvement, 246–248  
 bovine pericardium patches, 247, 247f  
 cardiopulmonary bypass, 246  
 hilar vessels, 246  
 intracavitary cardiac involvement, 246  
 MR imaging of HCC with tumor thrombus,  
 247f  
 protective Glissonian extensions, 246  
 reconstruction in segments 7 and 8, 246f  
 retrohepatic vena cava, 246  
 three-dimensional CT of HCC, 248f

- Hepatic venous pressure gradient (HVPG),  
114, 208, 241
- Hepatitis B surface antigen (HBsAg), 2,  
11, 346
- Hepatitis B virus (HBV)  
DNA virus, 2  
HBV genotypes, 2  
HBV vaccination, reduced incidence of  
HCC, 2  
HCC development by HBV, approaches, 2  
identification of HBsAg, importance, 2
- Hepatitis B virus reactivation/  
chemotherapy, 346
- Hepatitis C virus (HCV)  
classification based on nucleotide sequence  
homology, 3  
hepatocellular damage by oxidative  
stress, 3  
proportion of HCC related to  
HBV/HCV/non-viral factors  
(1992–2006), 4f  
RNA virus, 2  
role in HCC development, 3
- Hepatitis C virus infection, 220
- Hepatitis virus infection, 2–4  
HBV, 2  
HCV, 2–4
- Hepatobiliary neoplasia, primary and  
metastatic, 153
- Hepatobiliary surgeon, 87
- Hepatobiliary surgical techniques, 254
- Hepatocarcinogenesis, 1, 3, 5, 8f, 10, 25, 27,  
111, 359, 370, 377
- Hepatocyte growth factor (HGF), 155, 356f,  
359, 364, 373t
- Hepatocyte paraffin 1 antibody (HepPar1), 46
- Hepatologist, 81–82
- Hepatoma, laparoscopic liver resection for,  
210–215  
malignant liver tumors, 210  
techniques, 210–215  
argon beam coagulation, 214  
diathermy, 214  
extensive hilar dissection, 214  
falciform ligament, 212  
findings and results, 212t  
harmonic scalpel, 214  
hepatocellular cancer, 214  
intraoperative ultrasonography, 211  
lobectomy, 214  
supine position, 213  
surgical incision, 211  
trendelenburg position, 213  
vascular staplers, 213
- Hepatopulmonary shunting, 324–325
- Hereditary hemochromatosis (HH/HHC),  
11–12, 104–105
- HH/HHC, *see* Hereditary hemochromatosis  
(HH/HHC)
- High-dose chemotherapy, 84, 161–162,  
287–288
- High-grade dysplastic nodules, 43, 47t
- Hirata, A., 374
- Histidine-tryptophan-ketoglutarate (HTK), 251
- Histologic grading scheme of HCC  
Edmondson grading scheme of HCC  
grade I/II/III/IV, 38–39, 39f–40f  
by Liver Cancer Study Group of Japan  
moderately differentiated HCCs, 39  
poorly differentiated HCCs, 39  
undifferentiated HCCs, 40  
well-differentiated HCCs, 39
- Histologic patterns of HCC, 38–40  
histologic grading of HCC, 38–40  
Edmondson grading scheme, 38–40  
grading scheme by Liver Cancer Study  
Group of Japan, 39–40  
histologic subtypes, WHO  
classification, 38  
trabecular, pseudoglandular(acinar),  
compact, and scirrhous, 38, 38f–39f
- Histologic variants of HCC  
combined HCC and cholangiocarcinomas,  
42–43  
fibrolamellar HCC, 41–42  
precursor lesions, 43–45
- Histology, *see* Histologic grading scheme of  
HCC; Histologic patterns of HCC;  
Histologic variants of HCC
- HIV, *see* Human immunodeficiency virus  
(HIV)
- Hooking technique, 144–146
- HSCs, *see* Hepatic stellate cells (HSCs)
- HSP70, *see* Heat shock protein 70 (HSP70)
- Hsu, C., 376
- Human immunodeficiency virus (HIV), 57
- HVPG, *see* Hepatic venous pressure gradient  
(HVPG)
- Hyperinsulinemia, 7, 10, 28
- Hypertrophy of hepatic segments, 153–154
- I**
- Iannitti, D. A., 283
- IARC, *see* International Agency for Research  
on Cancer (IARC)
- IGF-1, *see* Insulin-like growth factor-1 (IGF-1)

- IGFBP-1, *see* Insulin growth factor binding protein-1 (IGFBP-1)
- Immunosuppression  
 liver transplantation for HCC  
 calcineurin inhibitors, 231  
 colorectal cancer, 231  
 immune system, 231  
 tumoricidal effect, 231
- Íñarrairaegui, M., 330
- Indications for ultrasound-guided liver resection  
 liver exploration, 138–140  
 CE-IOUS, 139–140  
 planning of the surgical strategy  
 defining tumor–vessels relationship, 141  
 extension of resection to whole liver parenchyma, criteria, 141–142, 143f  
 impact of IOUS, factors, 141  
 minimesohepatectomy, 141  
 SERPS, 141  
 resection guidance  
 compression of the portal branch, 143–144, 143f  
 hooking of the portal branch, 144  
 limited resection, 144–145  
 liver parenchyma dissection, 145–147  
 major hepatectomy, 147–148  
 postresectional control, 147  
 systematic segmentectomy, 143
- Indocyanine green (ICG) retention test, 114, 116, 157, 175, 208t, 209–210, 268
- Inferior vena cava (IVC), 37, 111, 124, 137, 142f, 189, 213, 241–242, 247f–248f, 249–250, 264, 264f
- Inherited diseases  
 $\alpha_1$  antitrypsin deficiency, 12  
 HHC, 11–12
- In situ* hypothermic perfusion, 250–254  
 anterior wall, 251  
 cannulated portal vein, 251  
 IVC flow, 251  
 parenchymal transection, 251  
 portal/hepatic arterial inflow, 252  
 retrohepatic IVC, 251  
 suprahepatic caval clamp, 252  
 vascular anastomosis, 251  
 veno-venous bypass, 251
- Insulin growth factor binding protein-1 (IGFBP-1), 7
- Insulin-like growth factor-1 (IGF-1), 7, 9
- Insulin receptor substrate-1 (IRS-1), 7
- Intermittent clamping, 189
- International Agency for Research on Cancer (IARC), 2, 4–5
- Interventional radiologist, 84
- Intra-ablation imaging, 281
- Intracorporeal suturing, 211, 214
- Intrahepatic vasculature, 239, 251
- Intraoperative ultrasonography (IOUS), 122, 135–141, 136f, 140f, 143–148, 143f, 211, 262, 263f  
*See also* Contrast-enhanced intraoperative ultrasonography (CE-IOUS)
- Intra-tumoral chemotherapy concentration, 294
- Ionic polarization, 276
- IOUS, *see* Intraoperative ultrasonography (IOUS)
- Ipsilateral liver, 154
- IRS-1, *see* Insulin receptor substrate-1 (IRS-1)
- Ischemic preconditioning (IP), 243–244
- IVC, *see* Inferior vena cava (IVC)
- J**
- Jak/Stat pathway, 371
- Japanese algorithm for resection in cirrhosis, 115f
- Japanese Integrated Staging (JIS) score, 69, 72–73, 73t
- Jet cutter, 125
- JIS Score, *see* Japanese Integrated Staging (JIS) Score
- Johnson, P. J., 337–348
- K**
- Kamel, I. R., 327
- Kane, R. C., 361
- Karnofsky performance status, 323
- Kaseb, A. O., 1–12, 369–379
- Kawarada, Y., 156
- Kennedy, A., 327
- Keppke, A. L., 327
- Kettenbach, J., 312t, 313t
- Kim, R. D., 239–255
- Kloop, C. T., 320
- Koffron, A. J., 186t, 189  
 “Koffron quick stitch,” 214
- Kokudo, N., 89–96
- Kulik, L. M., 330–331
- L**
- Lamivudine, 82, 346–347
- Lam, V. W., 266
- Laparoscopic liver resection for HCC, 185–202  
 evaluation  
 comparison with open liver resections, 195



- learning curve, 195–197
- left lateral sectionectomy, 197
- major hepatectomy, 198–200
- other minor resections, 198
- indications
  - liver function, 192–193
  - tumor location, 191
  - tumor size, 192
- oncological results, 200–201
- resection and liver transplantation, 201–202
- series of laparoscopic liver resections, 186f
- surgical technique
  - liver mobilization and inflow/outflow control, 189
  - parenchymal transection, 189–190
  - patient positioning, 187
  - pedicle clamping, 189
  - pneumoperitoneum, 187–188
  - port placement for resection of lesions
    - located in segment 6, 188f
  - port sites positioning and hand assistance, 188–189
  - specimen extraction, 190
- Laparoscopic liver resection for hepatoma, 210–215
  - See also* Hepatoma, laparoscopic liver resection for
- Laparoscopic liver segments, 198
- Laparoscopic liver surgery, management of HCC, 207–216
  - functional reserve of liver, 209–210
  - imaging, 209
    - formation of metabolites, 209
    - lobar resection, 210
    - MR imaging, 209
    - residual liver volume, 209
    - triple phase CT scan, 209
    - ultrasound, 209, 212, 214
  - laparoscopic liver resection for hepatoma, 210–215
    - history, 210
    - preferred techniques, 213–215
    - technique, 210–213
    - See also* Hepatoma, laparoscopic liver resection for
- results, 215–216
  - ascites, 215
  - blood transfusion, 215
  - mean operating time, 215
  - mean surgical margin, 216
  - mortality rate, 215
  - open resection, 215
  - portal triad clamping, 215
    - transient liver failure, 215
  - selection of patients for surgery, 208–209
    - hypervascular lesion, 209
    - imaging/evaluation, 208
    - resection/ablation of lesion, 209
- Laparoscopic major hepatectomy, 198–200
- Laparoscopic right hepatectomy, 187, 189, 191
- Laparoscopic right posterior sectionectomy, 198
- Laparoscopic segments, 191, 191f
- Laparotomy, 140, 163, 193, 195, 214, 228, 280
- Large cell dysplasia, 43
- Laser ablation, 207
- Lauwers, G. Y., 35–48
- Lau, W. Y., 119, 329
- LCSGJ Staging System, 69, 72
- Learning curve effect, 195, 197, 229
- Left lateral sectionectomy, 189, 197, 197f, 202
- Lencioni, R., 266, 269, 311–314
- Lewis, A. L., 301
- Lin, S. M., 269
- Lipiodol, 84, 171–172, 223, 270, 289f–290f, 291, 294, 295f, 301
- Lipiodol–cisplatin chemoembolization, 291
- Lithotomy position, 211
- Liu, C. L., 111, 122
- Liu, D. M., 329
- Liver adenomas, 27–28
- Liver cancer, biological features, 23–24
  - angiogenesis, 25–27
  - genetic aberrations in HCC, 24
  - HCC from viral hepatitis/liver cirrhosis, 23–24
  - HCC in non-cirrhotic liver, 27–28
    - See also* Non-cirrhotic liver cancer
  - liver stem cells, 24–25
  - metastasis, 29–30
  - telomere shortening, 27
- Liver Cancer Study Group of Japan (LCSGJ), 36, 39, 69, 72, 92, 93–95, 127
- Liver function, 192–193
  - Child–Pugh A patients, 192
  - Child–Pugh B, 192
  - laparoscopic atypical resection of segment 2, 192f
  - portal hypertension, 192
  - tests in eastern countries
    - aminopyrine clearance, 114
    - galactose elimination capacity, 114
    - ICG clearance test, 114
- Liver mobilization and inflow/outflow control, 189

- Liver parenchyma dissection, ultrasound
  - resection guidance, 145–147
  - backflow bleeding, outcomes/control, 146–147
  - hooking technique, 145
    - example, 146, 147f
  - IOUS aid, advantages, 145–146
    - visualization of dissection line (DL), 146f
- Liver regeneration
  - mechanisms of, 154–155
    - “compensatory hyperplasia”, 154
    - “hyperplasia”, 154
    - “hypertrophy” 154
    - insulin, 155
    - partial hepatectomy in animal models, 155
  - rate of, 155–156
    - cirrhotic liver, 155
    - DNA synthesis, 155
    - fibrosis, 155–156
    - hepatocyte mitoses, 155
    - hepatocyte regeneration, 155
    - non-cirrhotic livers, 156
    - non-parenchymal cells, 155
    - pancreatectomy, 156
    - steatosis, 156
- Liver resection and liver transplantation, 89, 201–202
  - advantages and disadvantages, 202
  - “bridge” resection, 202
  - resection as tool, 202
  - “salvage” liver transplantation, 202
  - subsequent liver transplantation, risk factors, 202
- Liver resection for HCC
  - outcome after resection
    - fibrolamellar variant of HCC, 128–129
    - long-term outcome, 127–129
    - morbidity and mortality, 126–127
    - resection prior to liver transplantation, 127–128
  - preoperative assessment
    - assessment of tumor extent, 111–113
    - evaluation of FLR volume, 115–116
    - evaluation of hepatic function, 113–115
    - patient selection/preparation, 110
    - preoperative therapy, 116–120
    - prevention and control of bleeding, 124–126
    - surgical technique, 120–124
    - See also* Preoperative assessment in liver resection
- Liver resection (laparoscopic), evaluation, 194t
  - benefits, 194
  - comparison with open liver resections, 195
  - gas embolism and bleeding, 195
  - hand-assisted laparoscopic resection, 211
  - laparoscopic-assisted (hybrid) open resection, 211
  - laparoscopic atypical resection of segment 8 for HCC, 199f
  - laparoscopic segmentectomy 4b for HCC, 198t
  - laparoscopic vs. open liver resection for HCC, 196t
  - learning curve, 195–197
  - left lateral sectionectomy, 197
  - liver resections, complications of, 194
  - major hepatectomy, 198–200
  - minor resections, 198
  - morbidity rates after laparoscopic liver surgery, 194
  - pure laparoscopic, 211
  - See also* Laparoscopic liver resection for HCC
- Liver stem cells, 24–25
  - proliferation pathways, 25
  - self-renewal methods, 24
  - transformation into cancer cell, mechanisms, 25
- Liver transplantation for HCC, 219–232
  - cadaveric liver allografts/transplants, 220
  - current practice, 228
    - allograft dysfunction, 228
    - median MELD score, 228
    - orphan livers, 228
  - future perspectives, 231–232
    - controversial areas, 232t
    - molecular staging, 232
  - history of liver transplant, 219–220
  - immunosuppression
    - calcineurin inhibitors, 231
    - colorectal cancer, 231
    - immune system, 231
    - tumoricidal effect, 231
  - living donor liver transplantation, 228–229
    - cadaveric donor allografts, 228
    - mortality/recurrence rates, 228–230
  - neoadjuvant therapies, 223–225
  - outcomes and determinants
    - hepatic venous structures, 229
    - “high-risk” HCC, 230
    - microvascular invasion, 230
    - Milan Rule, 229–230
    - multifocality/satellitosis, 230

- pre-transplant AFP levels, 230
- tumor differentiation, 230
- in post “milan criteria” era, *see* Neoadjuvant therapies
- pre- and post-transplant metastasis screening, 222–223
- See also* Pre- and post-transplant metastasis screening
- staging systems in pre-transplant decision-making, 220–222
- See also* Staging systems in pre-transplant decision-making, HCC
- Llovet, J. M., 92, 290, 292, 304
- Lo, C. M., 291, 389
- Louafi, S., 376
- Low-grade dysplastic nodules, 43, 47f
- Lymphoproliferative disorders, 288
  
- M**
- Macronodular cirrhosis, 222
- Macroscopic classification of HCCs, 36
  - HCC, a multicentric disease, 36
  - intravascular and biliary growth, 36–37
  - nodular/massive/diffuse types (Eggel’s classification), 36
- Macroscopic features of HCC, 35–36
  - HCCs in cirrhotic/noncirrhotic livers, 35
  - intrahepatic/extrahepatic metastasis related to tumor size, 36
  - macroscopic classification of HCCs, 36–37
  - macroscopic appearance of HCC, 37f
  - peritumoral capsule, improved survival rates, 36
- Madoff, D. C., 153–178
- Magnetic resonance imaging (MRI), 55, 110–111, 128, 220, 242, 377, 384
- Major hepatectomy, 76, 115, 117–118, 118f, 126, 141, 147–148, 153–154, 156, 160–161, 175, 176f, 198–200, 241, 243, 268
- Makuuchi, M., 114, 120, 122, 154, 156
- Malagari, K., 306, 312–313
- Malignant neoplasms, 208, 275
- Mancinelli, R., 4
- MAPK, *see* Mitogen activated protein kinase pathway (MAPK)
- Martin, R. C. G., 99–106, 275–283, 299–315
- Massive HCCs, 36
- Masuzaki, R., 55–65
- Matrix metalloproteinases (MMP), 288
- Mazzella, G., 11
- McMasters, K. M., 81–87, 383–389
- M.D. Anderson Cancer Center, 109–111, 129, 161, 164, 177, 265
- M.D. Anderson Cancer Center, criteria for liver resection, 110t
- MDCT, *see* Multidetector CT (MDCT)
- Mechanisms of histogenesis for hepatocytes/cholangiocytes, 42
- Medical oncologist, 84
- Megestrol, 342
- Metabolic syndrome (MS), 28, 105
- Metastasis
  - HCC vs. solid tumours, 30
  - intrahepatic HCC metastases, diagnostic problems, 29
  - metastatic dissemination or multifocal tumour, 29
  - models of metastasis development, 30
  - molecular examples and pathways, 29, 29t
- Micrometastatic disease, 219
- Microscopic features of HCC, 37
  - cytologic subtypes of HCC, 40–41
  - histologic patterns of HCC, 38–40
- Microsphere Embolotherapy, 320–322
- Microsulis system, 278t, 279
- Microtaze system, 278t, 279, 282
- Microwave ablative technique, 84, 207, 275–283
  - choice of approach, 280–281
  - endotracheal anesthesia, 280
  - intra-ablation imaging, 281
  - laparoscopic/thoracoscopic approach, 280
  - open laparotomy, 280
  - radical resection, 281
  - radiofrequency ablation, 281
  - ultrasound, 281
- clinical use, 281–283
  - bile duct stenosis, 282
  - colon perforation, 286
  - concomitant hepatectomy, 283
  - potential asymptomatic pleural effusions, 282
  - skin burn, 282
  - transarterial chemoembolization, 283
  - Valley Lab Evident-based system, 283
- equipments, 278–279
  - coagulation zone, 279
- Evident™ Microwave Ablation System, 279
  - low-loss flexible coaxial cable, 278–279
  - magnetron, 278
  - microwave antenna, 278
  - microwave generator system, 279

- Microwave ablative technique (*cont.*)  
 resonance cavities, 278  
 therapeutic efficacy, 278  
 UMC-I microwave system, 279  
 indications, 280  
 alcohol, 280  
 hemihepatectomy, 280  
 hepatitis B/C, 280  
 hepatocellular carcinoma lesion, 280  
 tumor biology, 280  
 mechanism and theoretical benefits,  
 276–278  
 cellular death, 276  
 coagulation necrosis, 276  
 dielectric properties, 276, 277f  
 electromagnetic method, 276  
 heat sync effect, 277  
 ionic polarization, 276  
 microwave ablation devices and  
 corresponding frequencies, 276f  
 microwave generators, 278t  
 microwave's oscillating electric  
 field, 276  
 RFA heating, 277  
 tissue desiccation, 277
- Microwave antenna, 278
- Microwave-based devices, 190
- Microwave coagulation therapy (MCT), 277
- Microwave generator system, 279
- Microwave's oscillating electric field, 276
- Milan criteria, 72, 85, 92, 201, 207, 221,  
 225–228, 226t, 232t, 270, 293
- Milan/San Francisco transplantation, 293
- Minagawa, M., 113
- Mini-laparotomy, 193
- Minimesohepatectomy, 141
- miRNA, 24, 30
- Mitogen activated protein kinase pathway  
 (MAPK), 29
- Mitomycin C, 293
- Mitosis, 154–155
- Model for end-stage liver disease  
 (MELD), 220
- Models of metastasis development, 30
- Moderately differentiated HCCs, 39
- Molecular examples/pathways in metastasis,  
 29–30, 29t  
 MAPK pathway, 29  
 Wnt/ $\beta$ -catenin pathway, 29
- Molecular markers, 384
- Molecular target–targeted agent  
 relationship, 371
- Monoethylglycinexylidide (MEGX), 210
- Monopolar irrigated coagulation devices, 190
- Montorsi, M., 266–267
- Morino, M., 194
- MR angiography/venography, 242
- MS, *see* Metabolic syndrome (MS)
- Mucin, 42, 45
- Multidetector CT (MDCT), 62
- Multidisciplinary care of HCC patient  
 hepatobiliary surgeon  
 hepatic artery embolization for  
 70-year-old male with elevated  
 transaminases, 85f  
 impediments to initial resectability, 87  
 54-year-old male with multiple bilateral  
 liver nodules, unresectable case, 86f  
 hepatologist, 81–82  
 development of more comprehensive  
 HCC staging system, aim, 82  
 management of chronic cirrhosis/viral  
 hepatitis, 81  
 RCTs, efficacy of antiviral  
 medication, 81  
 role as health-care provider, 82  
 screening of at-risk population,  
 guidelines, 82  
 interventional radiologist  
 ablative modalities in non-eligible  
 patients for resection, 84  
 liver-directed procedures, assistance  
 for, 84  
 preoperative PVE, goal, 84  
 TACE, randomized arterial emboliza-  
 tion trials, 84  
 medical oncologist  
 sorafenib, molecular targeted  
 therapies, 84  
 systemic therapy for HCC, use of, 84  
 pathologist, 83–84  
 alpha-fetoprotein, biomarker used, 83  
 identification of fibrolamellar variant of  
 HCC, 84  
 identification of type/degree of vascular  
 invasion and fibrosis/cirrhosis, 83  
 radiologist  
 detection and characterization of tumor  
 masses, 82  
 measure of segmental liver volumes for  
 hepatic resection, 83  
 optimal imaging modality, recommen-  
 dations, 82–83  
 transplant surgeon, 85–86  
 Milan criteria, 85  
 role of, in multidisciplinary team, 86

- transplantation/resection, choice of, 85
- UCSF criteria, 85
- Multifocal HCC, 29, 72, 74, 74t, 112, 122, 224, 262, 268, 271, 299, 307, 320, 320f, 328, 385
- Multinodular HCC, 111–112
- Murthy, R., 319–332
- Mutha, P., 319–332
- N**
- NAFLD, *see* Non-alcoholic fatty liver disease (NAFLD); Non-alcoholic fatty liver disease (NAFLD)
- Nagino, M., 160, 164, 168, 170
- Nagorney, D. M., 129
- NASH, *see* Non-alcoholic steatohepatitis (NASH)
- NASH, stages in HCC mechanism, 8, 8f
- Nathan, H., 69–78
- National Cancer Institute, 61, 265, 268
- National Institutes of Health, 82
- Neoadjuvant therapies, 223–225
  - HCC Tumor Ablation, 224
    - anatomic tumor characteristics, 224
    - cryoablation, 224
    - radiofrequency ablation, 224
  - liver transplantation in post “milan criteria” era, 225–228
    - comparison of survivals, 226t
    - downstaging, 228
    - preoperative imaging, survival by, 226f
    - survival probability according to size, 227f
    - tumor diameter, 226
    - UCSF criteria, 225
  - liver transplant waitlist, 223
  - microwave ablation, 224
  - percutaneous ethanol injection, 223
  - radioembolization with Y-90, 224
    - arteriogram, 224
    - broader dispersion, 224
    - hepatopulmonary shunts, 224
    - nuclear colloid scan, 224
    - yttrium-90 (Y-90), 224
  - radiofrequency ablation (RFA), 224
  - systemic chemotherapy, 223, 225
    - hepatic artery thrombosis, 225
    - oral multikinase inhibitor, 225
    - sorafenib post-transplant, 225
    - stage IV HCC, 225
    - vascular endothelial growth factor receptor, 225
  - TACE, 223–224
    - chemotherapeutic agent, 223
    - embolic agent, 223
    - lipiodol, 223
    - median waitlist times, 223
    - systemic chemotherapy, 223
    - tumoral necrosis, 223
  - transarterial chemoembolization (TACE), 223
- Neuhaus, P., 129
- Nexavar®, 369, 373
- Ng, I. O., 111
- Nodular HCCs, subtypes, 36
- Nolatrexed, 338t, 340
- Non-alcoholic fatty liver disease (NAFLD), 28, 100, 105–106
- Non-alcoholic steatohepatitis (NASH), 7, 105, 167f
- Non-cirrhotic liver cancer, 27–28
  - conditions, 27
  - liver adenomas
    - β-catenin-activated adenomas, higher risk of HCC, 28
  - potential causes, 100f
  - risk factors
    - HCC risk in diabetic patients, 28
    - iron overload, 28
    - MS with fatty liver disease/liver adenomas, 28
    - uninodular/encapsulated/expansive growing tumours, 27
- Non-Hodgkin’s lymphoma, 288
- Non-neoplastic liver parenchyma, 288
- Novel approaches to cytotoxic chemotherapy
  - AFP as biomarker, 346
  - drug resistance, strategies
    - bortezomib, anti-tumour activity of, 345
    - MDR1, over-expression, 345
    - proteosome, 345
  - HBV reactivation/chemotherapy, 346–347
- O**
- Obesity
  - and HCC, obstacles, 8
  - lipid peroxidation/free oxygen radicals, role in NASH
    - HCC mechanism, stages in, 8, 8f
    - US case–control study, BMI evaluation, 8–9, 9f
- Octreotide, 342–343
- Ogata, S., 118, 174
- Okuda staging system
  - criticisms, 70
  - patients stratification, factors, 70
  - Stage I/II/III disease, defined, 70

- OLT, *see* Orthotopic liver transplantation (OLT)
- Omata, M., 55–65
- Oncogene, 3, 24, 26, 370
- Oncological results, 200–201
- chronic liver hepatitis or cirrhosis, 200
  - feasibility of redo laparoscopic treatment, 200
  - laparoscopic liver resections for HCC, 201t
  - liver transplantation after laparoscopic left lateral sectionectomy, 199f
  - multicentric carcinogenesis, 200
  - surgical margin width, 200
- Oncologic indications, 219
- Oncologic tumor clearance, 239
- O’Neil, B. H., 376
- Open laparotomy, 280
- O’Reilly, E.M., 355–365
- Orthotopic liver transplantation (OLT), 109, 293
- Oxaliplatin, 162, 341, 346, 364
- Oxidative stress, 3, 5, 7, 12, 28
- P**
- Palavecino, M., 117, 175
- Palmer, D., 337–348
- Parenchymal dissection techniques, 125
- argon beam coagulator, 125
  - jet cutter, 125
  - saline-linked cautery (SLC), 125
  - two-surgeon technique, 125–126, 125f
  - ultrasonic dissector, 125
- Parenchymal transection, 188–189
- other devices, 190
  - radiofrequency-assisted hepatic resection, 190
  - stapler hepatectomy, 190
  - ultrasonic aspirator, 190
  - ultrasonic scalpel, 190
  - vessel sealing system, 190
- Pastorelli, D., 376
- Pathologic considerations
- ancillary studies
    - benign vs. malignant hepatic tumors, adjunct methods in, 46–48
    - HCC vs. metastatic adenocarcinoma/ cholangiocarcinoma, 45–46
  - histologic variants of HCC
    - combined HCC and cholangiocarcinomas, 42–43
    - fibrolamellar HCC, 41–42
    - precursor lesions, 43–45
    - macroscopic features of HCC, 35–37
    - macroscopic classification of HCCs, 36–37
    - microscopic features of HCC, 37–41
      - cytologic subtypes of HCC, 40–41
      - histologic patterns of HCC, 38–40
- Pathologic staging systems
- AJCC/UICC staging system, 74–75
  - choice of appropriate staging system, 76–77
  - CUPI staging system, 73–74
  - JIS staging system, 72–73
  - LCSGJ staging system, 72
- Pathologist, 83–84
- Pawlik, T. M., 69–78
- PDGFR, *see* Platelet derived growth factor receptor (PDGFR)
- Pedicle clamping, 189
- PEI, *see* Percutaneous ethanol injection (PEI); Percutaneous ethanol injection (PEI)
- Percutaneous ablation therapy
- PEI, 89
  - RFA, 89
- Percutaneous alcohol injection, 207
- Percutaneous ethanol injection (PEI), 89, 223, 268, 269t, 300, 385
- Percutaneous radiofrequency ablation, 185
- Perioperative hepatic failure, 153
- Peritumoral capsule, 36
- Pinna, A. D., 129
- Platelet derived growth factor receptor (PDGFR), 119, 357, 374
- Pleomorphic HCCs, 40
- Pneumoperitoneum, 187–188
- Pochin, E. E., 321
- Polyclonal CEA and CD10, 46
- Polyvinyl alcohol (PVA), 172, 223, 270, 301
- Poon, R. T. P., 128, 211, 302, 312–314, 383, 385–388
- Poorly differentiated HCCs, 39
- Porphyria Cutanea Tarda, 12
- Portal hypertension (PH), 85, 91, 113–114, 135, 161–162, 173, 192, 194, 208, 221, 228, 240–241
- Portal vein embolization (PVE), 84, 116–118
- See also* Preoperative PVE; PVE, indications and contraindications; PVE prior to resection; Technical considerations for PVE
- Portal venous thrombosis, 330
- Port placement and surgeon positioning, 211f
- Positron emission tomography (PET), 265

- Post-embolization syndrome, 328
- Post-liver transplant survivals,
  - comparison, 226t
- Postresectional control, 147
- PRb, *see* Retinoblastoma protein (pRb)
- Pre- and post-transplant metastasis screening
  - bone metastases, 222
  - restaging intervals, 223
  - UNOS T1/T2/T3 stage disease, 222
- Precursor lesions, 43–45
  - early HCCs, 43–44
    - nodule-in-nodule growth pattern, 45f
    - “stromal invasion” of intratumoral portal spaces, 44
  - high-grade dysplastic nodules, 43
  - low-grade dysplastic nodules vs. cirrhotic nodules, 43
  - vaguely nodular lesion in dysplastic nodules/early well differentiated HCC, 43, 44f
- Preoperative assessment in liver resection
  - assessment of tumor extent
    - contraindications for resection, 111
    - large tumor size, 111, 112f
    - major portal or hepatic vein involvement, 112–113
  - MRI, preoperative imaging, 110–111
  - multinodular disease, 111–112
  - patient staging with triple phase, 110
  - tumor recurrence, early/late, 113
- evaluation of FLR volume, 115–116
  - postoperative complications,
    - predictions, 116, 117f
  - preoperative liver volume calculation
    - by three-dimensional CT volumetry, 115, 116f
- evaluation of hepatic function, 113–115
  - Child–Pugh classification, 113–114, 113t
  - Japanese algorithm for resection in cirrhosis, 115f
  - liver function tests in eastern countries, 114
  - portal hypertension, complications, 114
  - postoperative mortality, 114
- M.D. Anderson Cancer Center, criteria for resection, 110t
- patient selection/preparation, 110
- preoperative therapy
  - chemotherapy, 118–120
  - PVE, perioperative outcomes/survival rates, 116–120, 118f
  - sequential arterial and portal vein embolization, 120f
  - TACE, 116–118
- prevention and control of bleeding,
  - 124–126
  - blood loss due to pressure within IVC, 124–125
  - drainage, 126
  - hepatic pedicle clamping,
    - drawback, 124
  - indications for TVE, 124
  - parenchymal dissection techniques, 125
  - Pringle maneuver, randomized study, 124
  - temporary vascular occlusion,
    - techniques, 124
- surgical resection/OLT, treatment options, 109
- surgical technique, 120–122
  - anatomic resection, 120
  - resection of large right liver tumors, 122–124
- Preoperative PVE, 153, 243
  - pathophysiology of, 156–157
    - biliary excretion, 156
    - Doppler sonography, 157
    - left liver hypertrophy prior to right hepatectomy, inducing, 156
    - liver function tests, 156
    - parenchymal or tumor necrosis, 157
    - technetium-99m-galactosyl human serum albumin uptake, 156
  - Pringle maneuver, 124
- Protein RKIP (Raf kinase inhibitory protein), 371
- Proteosome, 345
- Pulmonary embolism/metastasis, 246
- PVA, *see* Polyvinyl alcohol (PVA)
- PVE, *see* Portal vein embolization (PVE); Portal vein embolization (PVE)
- PVE, indications and contraindications
  - general contraindications, 162
    - ipsilateral tumor, 162
    - portal hypertension, 162
  - general indications, 159–160
    - diabetes, 159
    - non-hepatic surgery, 159
    - protein synthesis, 159
    - regenerative capacity of liver, 159
- high-dose chemotherapy, 161–162
  - bevacizumab, administration of, 162
  - hepatic hypertrophy, impact on, 162
  - hepatic injuries, 162

- PVE, indications and contraindications (*cont.*)
- preoperative chemotherapy, 162
  - preoperative systemic or regional chemotherapy, 161
  - steatosis, complications after resection, 161
- normal underlying liver, 160
- extended left hepatectomy with caudate lobectomy, 160
  - FLR/TELV, complications, 160
  - liver volume analysis, 160
- underlying liver disease, 160–161
- advanced liver disease, 161
  - chronic liver disease, 161
  - extended hepatectomy, 159
  - hepatic fibrosis by core needle biopsy, assessment of, 161
  - “liver disease,” 161
  - major hepatectomy, 160–161
  - mild portal hypertension, 161
  - sequential chemoembolization and PVE, 161
- PVE prior to resection, 153–178
- clinical use, 153
  - complications, 173
    - complete portal vein thrombosis, 173
    - technical complications with percutaneous PVE, 173
    - transhepatic procedures, complications, 173
  - FLR volume measurement and functions, 157–159
  - indications and contraindications
    - general contraindications, 162
    - general indications, 159–160
    - high-dose chemotherapy, 161–162
    - normal underlying liver, 160
    - underlying liver disease, 160–161
  - liver regeneration, mechanisms of, 154–155
  - outcomes and hepatectomy for HCC, 173–177
    - American Joint Committee on Cancer stage, 175
    - combination of chemoembolization of tumor, 175
    - degree of parenchymal fibrosis, 173
    - disease-free survival, 175
    - FLR hypertrophy after PVE, 174t
    - hepatectomy outcomes, 174
    - mortality and postoperative complications after PVE, 176t
    - pre-PVE lower functional liver ratio, 174
    - residual volume, 175
    - RPVE, 177
    - slower regeneration rates, 173
  - pathophysiology of preoperative PVE, 156–157
  - rate of liver regeneration, 155–156
  - technical considerations
    - additional PVE approaches, 168–170
    - embolic agents, 171–172
    - extent of embolization, 170–171
    - standard approaches, 162–165
- R**
- Radiation-induced liver disease (RILD), 328
- Radiation “segmentectomy,” 331
- Radiofrequency ablation (RFA), 71t, 71, 77, 89, 111, 127, 185, 200, 201, 207, 215, 223–224, 261–271, 276, 280–283, 292, 300, 315, 383
- bridge therapy to transplantation, 270
    - donor liver, 270
    - Milan criteria, 270
    - multifocal HCC, 271
    - survival rates, 270
  - in combination with surgical resection, 268
    - bilobar tumors, 268
    - hepatectomy, 268
    - hepatic resection, 268
    - indocyanine green dye retention rate, 268
    - liver-directed therapy, 268
    - multivariable analysis, 268
    - open RFA, 268
    - percutaneous approach, 268
  - comparing RFA to ablative techniques, 268–269
    - freeze-thaw cycles, 269
    - morbidity rate, 269
    - percutaneous ethanol injection, 269t
    - subzero temperature, 268–269
    - survival/local recurrence rates, 269
    - tissue freezing, 269
    - tumor size, 268
  - comparing RFA to surgical resection, 267
    - disease-free survival, 267
    - hepatic function, 267
    - survival rates, 267
    - tumor necrosis, 267
  - hepatitis B/C viral infections, 261
  - imaging considerations, 264
    - detection rate, 265
    - dynamic imaging, 265
    - inflammatory tissue, 266



- multiphasic helical CT, 264
    - necrotic cavitory lesion, 264
    - serial dynamic MRI, 264
    - surveillance post-RFA, 265
    - tumor recurrence, 265
  - indications, 265–267
    - Childs–Pugh class, 266
    - extra-hepatic disease, 265
    - hepatic arterial embolization, 265
    - intra-hepatic recurrence, 267
    - intra-tumoral bleeding, 265
    - long-term survival and local recurrence results, 266t
    - mortality rate, 267
    - subcutaneous/subcapsular hematoma, 265
    - symptomatic pleural effusion, 265
    - thermal destruction, 266
    - tissue ablation, 265
    - ventricular fibrillation, 265
  - liver-directed therapies, 270
    - hepatic arterial perfusion, 270
    - median follow-up period, 270
    - survival benefit, 270
    - transarterial chemoembolization (TACE), 270
  - technical considerations, 264–266
    - closed loop circuit, 264
    - electrode–tissue interface, 264
    - fistulas, 264
    - hepatic inflow occlusion, 263
    - hepatic resection, 263
    - hypervascular tumors, 263
    - intra-tumoral electrode, 262
    - laparoscopic open approach, 262
    - multi-array probes, 262
    - percutaneous approach, 263
    - radiofrequency power density, 262
    - thermal tissue damage, 262
    - tissue coagulative necrosis, 262
    - transcutaneous visualization, 263
  - Radiofrequency-assisted hepatic resection (Habib Laparoscopic Sealer 4XL<sup>®</sup>), 190
  - Radiologist, 82–83
  - Raf kinase inhibitor protein (RKIP), 29–30
  - Randomized controlled trial (RCT), 92
  - Raut, C. P., 266
  - Ravindra, K., 207–216
  - RCT, *see* Randomized controlled trial (RCT)
  - Reactive oxygen species (ROS), 3
  - RECIST response criteria, treatment response assessment
    - complete response (CR), 304
    - partial response (PR), 304
    - progressive disease (PD), 304
    - stable disease (SD), 304
  - Retinoblastoma protein (pRb), 22
  - Retrohepatic inferior vena cava, 213, 247f, 250
  - RFA, *see* Radiofrequency ablation (RFA)
  - Rhee, T. K., 331
  - Riaz, A., 327
  - Ribero, D., 83, 173–174, 176
  - Right posterior sectionectomy, 141, 191, 198
  - Right PVE (RPVE), 163
  - RILD, *see* Radiation-induced liver disease (RILD)
  - Ringe, B., 129
  - Risk factors of HCC
    - chronic medical conditions
      - cholelithiasis (gallbladder stones), 10
      - diabetes mellitus, 7
      - obesity, 7–9
      - thyroid diseases, 9–10
    - dietary factors, 10
    - environmental risk factors
      - aflatoxin exposure, 6
      - alcohol consumption, 4–5
      - hormonal intake, 6
      - occupational exposures, 6
      - smoking, 5–6
    - genetic risk factors
      - familial aggregation, 11
    - hepatitis virus infection, 2–4
      - HBV, 2
      - HCV, 2–4
    - inherited diseases
      - $\alpha_1$  antitrypsin deficiency, 12
      - HHC, 11–12
  - RKIP, *see* Raf kinase inhibitor protein (RKIP)
  - RNA hepatitis C (Hep. C), 288
  - Romito, R., 330
  - ROS, *see* Reactive oxygen species (ROS)
  - ROS, proinflammatory mediators, 3
- S**
- Salem, R., 327, 329–330
  - Saline-linked cautery (SLC), 125
  - Sangro, B., 330
  - Santambrogio, 194, 201, 214
  - Scoggins, C., 99–106
  - Scoring systems, *see individual*
  - Screening program in high-risk populations
    - cost-effectiveness, 64–65
    - objective of screening and surveillance, 56
    - screening intervals, 63–64

- Screening program in high-risk populations  
(*cont.*)
- AASLD guidelines for ultrasound surveillance, 63
  - surveillance algorithm for HCC in Japan, 63, 64f
  - standardized recall procedures
    - increased AFP levels, findings, 62–63
    - ultrasonography, recommendations for HCC, 63
  - surveillance methodology
    - AFP, 58–60
    - combined AFP measurement and ultrasonography, 61
    - new serum markers and methods, 62
    - ultrasonography, 60–61
  - target population
    - assessment of liver fibrosis, importance, 57
    - chronic HCV infection in Japan/Europe/US, study, 57
    - cirrhosis, risk for HCC development, 57
    - HBV carriers, associated risk, 56–57
    - HBV/HCV infection variations
      - according to geographic area, 56
    - HCC screening, 56
    - HIV coinfection, risk factor of liver fibrosis (US), 57
  - Segmental portal venous occlusion in rabbits, effects of, 153
  - Seki, T., 282–283
  - Sequential arterial embolization, 168–170
    - “arterialization of the liver,” 168
    - arterioportal shunts, 168
    - chemoembolization, 170
    - FLR hypertrophy, 168
    - risks of hepatic infarction, 170
    - sequential transcatheter arterial chemoembolization, 169f
    - tumor necrosis, 170
  - SERPS, *see* Systematic Extended Right Posterior Sectionectomy (SERPS)
  - Serum alanine aminotransferase levels, 242
  - Sex hormone-binding globulin (SHBG), 10
  - Shah, S. A., 385
  - SHARP trial, 357
  - SHBG, *see* Sex hormone-binding globulin (SHBG)
  - Shepherd, 321
  - Shiina, S., 269
  - Sirolimus, 231
  - SIR-spheres<sup>®</sup>, 322–324, 326
  - Somatostatin analogues
    - HECTOR study, 342
    - heparan sulphate, degradation of, 344
    - polyprenoic acid, 343
    - SSTR, overexpression of, 342
  - Somatostatin receptor (SSTR), 342
  - SonoVue<sup>®</sup>, 136, 363
  - SonoVue R (Bracco) bolus injection, 363
  - Sorafenib
    - side effects, 357–368
    - two phase III studies, 357
  - Soreide, O., 129
  - Spindle (sarcomatoid) tumor cells, 40f, 41
  - SSTR, *see* Somatostatin receptor (SSTR)
  - Staging of HCC
    - clinical staging systems
      - BCLC staging system, 71–72, 71t
      - CLIP, 70–71, 70t
      - Okuda staging system, 70
    - pathologic staging systems
      - AJCC/UICC staging system, 74–75
      - choice of appropriate staging system, 76–77
      - CUPI staging system, 73–74
      - JIS staging system, 72–73
      - LCSGJ staging system, 72
  - Staging systems in pre-transplant decision-making, HCC, 220–222
    - clinical significance of serum alpha-fetoprotein, 222
    - portal hypertension, 221
    - portal pressure measurement, 221
    - radiologic staging, 220
    - survival rate, 222
    - tissue biopsy, 221
    - UNOS staging system for HCC, 221t
    - vascular invasion, 221
  - Stapler hepatectomy, 190
  - Sunitinib
    - adverse events, 358
    - median overall survival, 359
    - treatment efficacy analysis, 358–359
    - VEGF/PDGF receptor pathways, 358
  - Sun, W., 380
  - Surveillance methodology
    - AFP
      - disadvantage as a tumor marker, 58–60
      - HCC screening of Alaskan carriers of hepatitis B, 58
      - surveillance studies for HCC, 59t
    - combined AFP measurement and ultrasonography, 61
    - new serum markers and methods

- DCP, AFP-L3, glypican-3, IGF-1, HGF, 61
- FDG-PET, 62
- MDCT outcomes, 62
- 5-phase program by EDRN, 62
- ultrasonography, 60–61
- CT or MRI studies, 60
- identification/detection of intrahepatic lesions, 60–61
- Systematic Extended Right Posterior Sectionectomy (SERPS), 141
- Systematic segmentectomy, 143–144
- Systemic chemotherapy, 84, 162, 223, 225, 228, 287, 294–295, 299, 303, 341, 343, 385
- T**
- TACE, *see* Transarterial chemoembolization (TACE)
- Takatsuki, M., 125
- Takayama, T., 144, 176
- Tamoxifen, 341–342
- Tanaka, H., 175–176
- Targeted anti-cancer agents, 372t
- Targeted therapies, HCC
- antiangiogenic drugs
    - bevacizumab, 358
    - erlotinib, 359–360
    - sorafenib, 357–358
    - sunitinib, 358–359
    - tyrosine Kinase Inhibitors (TKIs), 358–360
  - management issues
    - etiology, 360
    - liver function, impact of, 360–362
    - tumor assessment, 362–364
  - new drug development
    - IGF-II, up-regulation of, 364
    - phase II study, report, 364
  - therapeutic targets AND corresponding pathways, 356f
- <sup>99m</sup>Tc MAA, 321, 323, 329–330
- Technetium-99m-labeled diethylenetriamine pentaacetic acid-galactosyl-human serum albumin, 159
- Technical considerations for PVE
- additional PVE approaches
    - bland transarterial embolization, 168
    - sequential arterial embolization, 168–170
    - transjugular access, 170
  - See also* Embolization
  - embolic agents, 171–173
  - extent of embolization, 170–171
  - standard approaches, 162–167
    - balloon catheter for antegrade embolization, 164f
    - intraoperative transileocolic venous approach, 163
    - ipsilateral technique for RPVE, 165f
    - placement of occlusion balloon catheter, 163f
    - portal blood flow toward FLR, 162–163
    - transhepatic contralateral approach, 163
    - transhepatic ipsilateral RPVE, *see* Transhepatic ipsilateral RPVE
- Telomerase, 23, 27, 384
- Telomeres, 23, 27
- Telomere shortening, 27
- Temporary vascular occlusion, techniques, 124
- Thomas, M. B., 369–379
- Thoracoscopy, 191
- Three-dimensional CT volumetry, 115, 116f
- Thrombocytopenia, 114, 241, 341, 359
- Thyroid diseases, 9–10
- hypothyroidism and NASH, association, 9
  - SHBG, role in HCC, 10
- Tisseel (Baxter), 214
- Tissuelink™, 213
- TNM staging system, 82
- Torzilli, G., 135–148
- Total vascular exclusion (TVE), 124
- Total vascular isolation, 248–250
- central venous pressure, 249
  - ex vivo* resection techniques, 249
  - inflow occlusion, 249
  - ischemic liver injury, 249
  - IVC exclusion time, 249
  - normothermic conditions, 249
  - retrohepatic IVC, 249
  - suprahepatic /retrohepatic IVC, 249
- Transarterial chemoembolization (TACE)
- cell/chemical signaling, 288
  - clinical trials and current evidence, 291–293
    - cisplatin/doxorubicin, 293
    - DNA intrastrand crosslinks, 293
    - lipiodol–cisplatin chemoembolization, 291–291
    - mitomycin C, 293
    - pre-and post-TACE, 291f
    - radiofrequency ablation (RFA), 292
    - resection vs. locoregional treatments, 292

- Transarterial chemoembolization (TACE)  
*(cont.)*  
 survival of patients with resectable/unresectable HCC, 292f  
 three-month, sequential MRI, 291f  
 hepatotropic viruses, 287  
 intra-arterial locoregional treatment, 288  
 intra-tumoral drug concentration, 287  
 non-neoplastic liver parenchyma, 288  
 quality of life/toxicity profile, 293–294  
 ascites, 294  
 Child–Pugh C liver cirrhosis, 294  
 Common Terminology Criteria for Adverse Events (CTCAE), 294  
 Eastern Cooperative Oncology Group (ECOG), 294  
 edema/fatigue, 294  
 intra-tumoral chemotherapy concentration, 294  
 possible TACE-related complications, 294t  
 TACE, bridge to transplantation, 293  
 liver transplantation, 293  
 Milan/San Francisco transplantation, 293  
 orthotopic liver transplantation (OLT), 293  
 vascular anatomy of HCC, 288–292  
*See also* Vascular anatomy of HCC  
 VEGF receptor kinases, 288  
 Wilson’s disease, 287
- Transesophageal echocardiography study, 186
- Transforming growth factor- $\alpha$  (TGF- $\alpha$ ), 154
- Transhepatic contralateral approach, 163  
 advantages and disadvantages, 164  
 catheterization and embolization, 165  
 3-French microcatheter, 164  
 5-French reverse-curve catheter, 165  
 left lateral portal system, 163  
 multicenter European study, 164  
 Nagino’s ipsilateral technique, 164  
 tumor thrombus, progression of, 163
- Transhepatic ipsilateral RPVE  
 extended to segment 4, 166f  
 with particles and coils to right hepatectomy, 165f
- Transileocolic venous approach,  
 intraoperative, 163  
 disadvantages, 163  
 embolization, 163  
 interventional radiology suite, 163
- Transjugular intrahepatic portosystemic shunts (TIPS), 170
- Transplant surgeon, 85–86
- Transverse incision, 213
- Trastuzumab (Herceptin<sup>®</sup>), 371, 372t
- Treatment algorithm for HCC (Japan), 90f  
 advanced cancer  
 chemotherapy, 93  
 TACE and liver resection, 93  
 degree of liver damage A and B  
 liver resection/percutaneous ablation treatment, two/three tumor case, 92  
 liver resection, treatment of choice, 92  
 TACE/hepatic arterial infusion therapy, four or more tumors, 92  
 TACE, tumor diameter greater than 3 cm, 92  
 degree of liver damage C, 92–93  
 liver transplantation, recommendations, 93  
 Milan criteria, 92–93  
 selection of three important factors  
 degree of liver damage, 90–91, 91t  
 number of tumors, 92  
 tumor diameter, 92
- Treatment of HCC in Japan, evidence-based guidelines  
 Clinical Practice Guidelines for Hepatocellular Carcinoma (2005), 90  
 evaluation of algorithm  
 questionnaire survey, results of, 93, 93f  
 HCC vs. malignant tumors, characteristics, 89  
 methods of treatment  
 percutaneous ablation therapy, RFA/PEI, 89  
 surgery, liver resection/transplantation, 89  
 TACE, 89  
 revisions of the guidelines  
 adoption of RFA, effects, 94  
 RFA consequence, efficacy evaluation of treatments, 94  
 sorafenib efficacy against HCC, RCT results, 94  
 treatment algorithm  
 advanced cancer, 92  
 degree of liver damage A and B, 91  
 degree of liver damage C, 91–92  
 selection of three important factors, 89–91  
 use of algorithm

clinical practice guidelines, 92  
 method of treatment,  
     recommendations, 92  
 Trendelenburg position, 211  
 Tricuspid stenosis, 246  
 Tris-acryl gelatin microspheres, 171  
 T-stage HCC, 222  
 TSU-68, 373–374  
 Tumor location, 191, 191f  
 Tumor location, “laparoscopic segments,” 191f  
 Tumor markers, role, 384  
 Tumor necrosis, 362f  
 Tumor size, 192  
 TVE, *see* Total vascular exclusion (TVE)  
 Tyrosine Kinase Inhibitors (TKIs)  
     oral EGFR tyrosine kinase inhibitor, 359  
     varied EGFR ligands, 359

**U**

UDP-glucuronosyltransferase (UGT1A1), 361  
 Ultrasonic aspirator, 190  
 Ultrasonic dissector, 125  
 Ultrasonic scalpel, 190  
 Ultrasonography, 55, 58, 60–61, 63–64, 82,  
     214, 244, 263  
     *See also* Contrast-Enhanced Intraoperative  
     Ultrasonography (CE-IOUS);  
     Intraoperative ultrasonography  
     (IOUS)  
 Ultrasound-guided liver resection for HCC  
     indications  
         liver exploration, 140–142  
         planning of the surgical strategy,  
             141–143  
         resection guidance, 145–150  
         *See also* Indications for ultrasound-  
         guided liver resection  
     technical aspects  
         CEIOUS, rationale, 137  
         proper IOUS, probes required, 136  
         scanning area of IOUS image, 136f  
         ultrasound liver anatomy, 137–138  
 Ultrasound liver anatomy, 137–138  
     Brisbane Terminology, 137  
     IOUS study of the bile ducts, 138  
     probe management, 137  
 UMC-I microwave system, 279  
 Undifferentiated HCCs, 40  
 United Network for Organ Sharing (UNOS),  
     83, 220–222, 225, 227–230  
 United States National Comprehensive Cancer  
     Network (NCCN), 384  
 University of California San Francisco (UCSF)  
     criteria, 85, 207, 221

**V**

Valley Lab Evident-based system, 283  
 Varela, M., 302, 312–313  
 Vascular anatomy of HCC, 288–290  
     arteriolar/venular angiogenesis, 288  
     coronal T1- weighted, contrast-enhanced  
     MRI image of liver, 290f  
     European Association for the Study of  
     Liver (EASL), 290  
     interventional radiology, 288  
     response evaluation criteria in solid tumors  
     (RECIST), 290  
     “sump” effect, 288  
     vascular endothelial cells, 288  
     vascular supply of HCC, 289f  
 Vascular control during complex HCC  
     resections, 248–253  
     Ante situm procedure, 252  
         caval-hepatic vein junction, 252  
         IVC anastomosis, 252  
         IVC- hepatic vein junction, 252  
         pericardium, 252  
         situ cold perfusion, 252  
         suprahepatic IVC, 252  
         vein *en bloc*, 252  
     cold perfusion and *ex vivo*  
     approach, 254  
         retrohepatic inferior vena cava, 250  
         in situ hypothermic perfusion, 250  
     *ex vivo* liver resection, 253  
         benefit ratio, 253  
         combined hepatic vein, 253  
         dobutamine stress  
             echocardiogram, 253  
          hilar involvement, 253  
         long-term follow-up, 253  
         renal dysfunction, 253  
 Vascular endothelial growth factor (VEGF),  
     23, 26, 84, 118, 162, 225, 356f,  
     357–358, 372t–373t, 374  
 Vascular endothelial growth factor receptor  
     (VEGFR), 118–119, 225,  
     356–359, 374  
 Vascular inflow/outflow, 229  
 Vascular invasion in HCC, pathophysiology of  
     alpha-fetoprotein level, 241  
     arterial phase CT scan, 240  
     arterio-venous shunt, 241  
     cell–matrix interactions, 241  
     endothelial cells, 240  
     hepatic vein invasion, 241

- Vascular invasion in HCC, pathophysiology of  
(*cont.*)  
  intrahepatic metastases, 240  
  microscopic/macrosopic vascular  
  invasion, 240  
  portal hypertension, 240  
  portal vein tumor thrombus, 241  
  radiopaque injection, 240  
  tumor satellitosis, 240  
‘Vascular mimicry’/‘vasculogenic mimicry,’  
  26, 30  
Vascular or biliary injury, 191  
Vascular permeability ( $K^{\text{trans}}$ ), 363  
Vascular resection for HCC, 243–255  
  evaluation and work-up of patient with  
  HCC for resection, 241–243  
  pre-operative imaging, 242–243  
  underlying liver disease, 241–242  
  “extreme operations,” 255  
  hepatic resection with vascular  
  reconstruction, 244–245  
  *See also* Hepatic resection with vascular  
  reconstruction  
  hepatic vein and IVC involvement,  
  246–248  
  intraoperative strategies for hep-  
  atic/vascular resections, *see*  
  Hepatic/vascular resections,  
  intraoperative strategies  
  oncologic tumor clearance, 239  
  outcomes of resection of HCC with  
  vascular involvement, 254  
  HCC pulmonary emboli, 254  
  macrovascular/microvascular  
  invasion, 254  
  mean survival data, 254  
  multicenter review, 254  
  pathophysiology of vascular invasion in  
  HCC, *see* Vascular invasion in  
  HCC, pathophysiology of  
  portal vein embolization, 239  
  vascular control during complex HCC  
  resections, 250–255  
  ante situm procedure, 250–252  
  cold perfusion and *ex vivo*  
  approach, 250  
  *ex vivo* liver resection, 253  
  in situ hypothermic perfusion, 250–252  
  total vascular isolation, 248–250  
  *See also* Vascular control during  
  complex HCC resections  
  vascular inflow/outflow, 239
- Vauthey, J. N., 81–87, 109–129, 174, 174,  
  383–389  
VEGF, *see* Vascular endothelial growth factor  
  (VEGF)  
VEGFR, *see* Vascular endothelial growth  
  factor receptor (VEGFR)  
VEGF receptor kinases, 288  
Vennarecci, G., 386  
Vessel sealing system, 190  
Vigano, L., 185–203  
VMTN, *see* Volumetric measurement of  
  percent tumor necrosis (VMTN)  
Volumetric measurement of percent tumor  
  necrosis (VMTN), 363
- W**  
“Water bath” technique, 147  
Water jet dissection, 190  
Wei, A. C., 124  
Well-differentiated HCCs, 39  
Wilson’s disease, 12, 287  
Wollner, I., 321  
Woodall, C. R., 109–105  
World Health Organizations (WHO), 2, 305,  
  327, 357, 362, 377–378
- X**  
Xu, L., 8
- Y**  
Yamagiwa, K., 292  
Yamakado, K., 292  
Yamanaka, N., 282  
Yan, Z. P., 322  
Ya, P. M., 321  
Yttrium microspheres, 207  
Yttrium oxide, 321  
Yttrium-90 radioembolotherapy, hepatocellular  
  cancer  
  characteristics  
  zirconium production, 322  
  clinical studies  
  cumulative dose, portal vein  
  thrombosis, 330  
  multivariate analysis, 329  
  preliminary results, 330  
  retrospective analysis, 329  
  short/long survivors, 329  
  survival results, 330  
  dosimetry, 325–326  
  microsphere embolotherapy, development  
  of, 320–322  
  patient selection

- hepatic arterial supply and gastrointestinal ulceration, [328](#)
  - hepatopulmonary shunting, [324–325](#)
  - post-procedure evaluation
    - degree of necrosis, [327](#)
  - SIR-spheres and therasphere, [322–323](#)
  - toxicity, [328](#)
  - chemoembolization/radioembolotherapy
    - utilizing glass, comparison, [328](#)
    - liver abnormalities, [328](#)
  - Yu, M. W., [11](#)
- Z**
- Zhu, A. X., [376](#)
  - Zirconium, [322](#)
  - Zorzi, D., [109–129](#)